New York, USA – April 14, 2021 – DDA platform, the division of Creative Bioarray, is an innovative biotechnology branch that focuses on developing high quality products and technologies to facilitate the investigation of life science researches. With years of experience and professional team, DDA platform develops in vitro toxicology to accelerate the early stage of drug discovery with different set of techniques.
Creative Bioarray utilizes primary cells from many different tissues and organs and specializes in predictive, 3D tissue and cell-based in vitro toxicity assays. Creative Bioarray’s experienced scientists will work closely with customers to provide guidance for customers to follow the best strategy and which determinations should be prioritized at different stages of the discovery process to maximize the chances of success, save time and control costs.
Identifying potential toxicity in the early stages of drug discovery can save time and development costs, and most importantly, reduce the possibility of late failure. Before using animal models, in vitro procedures can be used to determine specific effects on cells and tissues. In vitro toxicity analysis includes applying new substances to mammalian cells that have been cultured in a single-layer 2D or biomimetic 3D structure, and monitoring their subsequent biochemical and phenotypic responses to identify cells that represent the results of toxicity.
The team of Creative Bioarray not only provides data, but also provides expertise to interpret the generated data. With the help of an established network of toxicology consultants and experts, additional support can be provided for the most challenging projects. Throughout the project, customers can access data at any time to facilitate discussion and decision-making. The available in vitro toxicology services available at Creative Bioarray include Cytotoxicity, Cardiotoxicity, Hepatotoxicity and Genotoxicity etc.
According to the recommendations of regulatory agencies, Creative Bioarray can provide a series of genotoxicity testing (non-GLP) services. If there are any positive reactions in an in vitro study, an in vivo study of the same endpoint is usually required. Genotoxicity testing of new chemical entities is an integral part of the drug development process and is a regulatory requirement before new drugs are approved. By determining genotoxicity early in drug discovery rather than during regulatory evaluation, the possibility of late failure can be reduced. In addition, Creative Bioarray provides a wide range of cytotoxicity assays for toxicology and pharmacology research. These assays have different classifications: 1) dye exclusion assays; 2) colorimetric assays; 3) fluorescence assays; and 4) luminescence analysis.
“Creative Bioarray is committed to becoming an ideal partner that can help customers use professional technology to understand the toxicity of compounds. We are committed to helping customers determine which compounds have the best safety and can enter clinical use,” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “We focus on the most advanced technology and automation to generate high-quality data quickly and cost-effectively.”
About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.